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a b s t r a c t
Peripheral neuropathy (PN) is a serious condition affecting the nerves that is commonly seen in patients with
tuberculosis (TB). Causes of PN in patients with TB are multiple, and can include TB itself, other co-morbid
conditions, such as Human Immune-deﬁciency virus (HIV) disease, malnutrition, or diabetes mellitus (DM),
and several anti-tuberculous medications. The condition can manifest with a variety of symptoms, and a
diagnosis can usually be made on a clinical basis. Treatment and prognosis of PN vary depending on the
underlying cause, but often the condition can lead to permanent disability in individuals with TB. For this
reason, primary prevention is key as is early identiﬁcation and management of symptoms. Treatment can
include withdrawal of possible offending agents, vitamin supplementation, physical therapy, analgesics, and
targeted agents, including tricyclic antidepressants, selective serotonin reuptake inhibitors, and gabapentin.
Additional research is needed to better describe the morbidity and disability associated with PN in persons
with TB and to improve management strategies for persons at risk for and affected by this condition. Case
review: RM is a 47 year-old man who is in his third month of treatment for drug-resistant TB (DR-TB). His
treatment regimen consists of kanamycin (1 gm intramuscular daily), levoﬂoxacin (1000 mg by mouth daily),
cycloserine (750 mg by mouth daily), ethionamide (750 mg by mouth daily), pyrazinamide (1500 mg by
mouth daily), and Para-Amino Salicylate (12 gm by mouth daily). He is HIV-infected with a CD4 count of
470 cell/μl and on a stable antiretroviral therapy regimen of tenofovir, lamivudine, and efavirenz, which he
started 8 weeks ago. He works in a platinum mine, denies smoking, reports drinking beer “on the weekend”
and denies other drugs. He presents for his 3 month clinical visit for his DR-TB follow-up and states he is
doing well, but he does report some “burning” in the bottom of his feet.
© 2015 The Authors. Published by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Peripheral nerves are parts of the nervous system responsible for
ransmitting information from all parts of the body to the spinal cord
nd brain [1]. Peripheral neuropathy (PN) is a condition in which the
erves are affected, compromising the relay of information from dif-
erent parts of the body. It can affect sensory nerves, motor nerves,
r autonomic nerves and cause a variety of symptoms and compli-
ations. It is estimated that as many as 500 million people in the
orld suffer from PN [2], and the problem is commonly seen among
ndividuals with tuberculosis (TB) [3]. The pathophysiology of PN re-
ults from an insult to the body of the nerve or to the myelin sheath,
eading to loss of normal function and development of deﬁcits in the
ffected individual [4]. With TB, there are a number of factors that
an lead to damage of the peripheral nerves and the development of∗ Corresponding author. Tel.: + 1 440 855 1395.
E-mail address: jenniferfurin@gmail.com (J. Furin).
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405-5794/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article undeeuropathy, including TB itself, other co-morbid conditions, and the
edications used to treat the disease [5].
pidemiology
Rates of peripheral neuropathy in the general population have
een noted to be around 1.1% but as high as 6% in the elderly, although
ost of this data come from western countries and there is a need
or more general baseline data in high-burden TB settings [6]. Several
tudies have assessed the prevalence of neuropathy in persons with
B. Among persons with drug-susceptible TB (DS-TB), rates between
and 10% have been reported in the literature [7]. In Swaziland, a
ohort of 250 patients from one hospital with drug sensitive tuber-
ulosis revealed a rate of 12%; however male patients had a higher
ate 18% compared to females 7% (p < 0.03); the older the patient,
he higher the rate of neuropathy (20% in those older than 45 years
ld compared to 9.6% in those less than 45 years old (p = 0.01) but
o signiﬁcant difference was demonstrated between those with HIVr the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
6 A.T. Mafukidze et al. / Journal of Clinical Tuberculosis and Other Mycobacterial Diseases 2 (2016) 5–11
i
b
t
e
s
c
m
N
m
t
i
a
p
t
d
t
d
i
t
c
c
t
ginfection and those without (13% vs 11%, p = 0.12) probably because
most of the HIV infected patients were already on ART prior to TB
disease and treatment [8].
For those with drug-resistant TB (DR-TB) much higher rates have
been seen, with studies reporting rates between 13 and 17% [9] Some
of the variation in rates may be due to the different drugs used and
the longer duration of treatment for DR-TB, but a recent study found
that as many as 25% of patients have PN at the time they start treat-
ment for DR-TB [10].
Etiology
There aremultiple potential causes of PN in personswith all forms
of TB. First, TB in and of itself has been associated with PN. This is felt
to be due to immune-mediated mechanisms, although there may be
more speciﬁc reasons, including granulomas in the nerves and depo-
sition disease (although to date this has only been reported in rare
cases of optic neuritis) [11,12]. In general, other causes of neuropa-
thy are sought before attributing causality to TB, and when TB is the
cause of neuropathy, the symptoms usually improve with treatment,
although this may take time [13]. There may also be some neuro-
logic syndromes caused by TB that mimic signs and symptoms of pe-
ripheral neuropathy, including spinal tuberculomas and meningeal
TB [14]. Of note, persons with TB may also experience other types of
inﬂammatory neuropathies from the disease or treatment, including
carpal tunnel syndrome and tenosynovitis [15]
Another common cause of PN in persons with TB is the existence
of co-morbid conditions that in and of themselves are associatedwith
PN [16]. Perhaps the most common co-morbid condition that is as-
sociated with PN and frequently seen in patients with TB is Human
immune-deﬁciency virus (HIV) disease [17], and in some populations
of TB patients, an HIV co-infection rate of upwards of 90% has been
reported [18]. Nutritional deﬁciencies—most notably of the B family
of vitamins—have also been associated with PN and are more com-
monly seen in individuals with all types of TB [19]. There is a global
epidemic of diabetes mellitus (DM) [20], and there is also emerging
evidence that diabetics are at increased risk for TB [21]. Given that
PN is commonly associated with DM and the growing associations
between TB and DM, there may be additional morbidity due to PN
in patients in this co-morbid population [22]. Finally, in some set-
tings, patients with high rates of substance abuse—especially alcohol
abuse—are at increased risk of TB [23], and these same populations
also have higher rates of PN as well [24]. Table 1 lists conditions com-
monly associated with TB that can also be associated with PN.
The third factor that is associated with TB and PN are the med-
ications used to treat TB. DS-TB is usually treated with a combi-
nation of four drugs given for a 6 month period. These drugs are
isoniazid (INH), rifampin (RIF), pyrazinamide (PZA) and ethambutol
(EMB), and of these medications, both INH and EMB have been asso-
ciated with neuropathy [25]. EMB is usually associated with the de-
velopment of optic neuritis/optic neuropathy but can be a rare cause
of reversible, distal sensory neuropathy. Streptomycin and the otherTable 1
Common co-morbid conditions seen with TB and PN.
Disease Comment
HIV Disorders of peripheral nerves are among the most frequent
associated with HIV treatment.
Malnutrition Most notably the B vitamin deﬁciencies
DM Diabetic neuropathy affects all peripheral nerves, which mea
Heavy metal toxicity More common in mining populations and in farm and factory
Compressive adenopathy A form of entrapment neuropathies where enlarged lymph n
mechanical constriction
Hypothyroidism A result of edematous inﬁltration of the endo- and perineuriu
Substance abuse Most notably alcoholismnjectable agents may cause cranial nerve VIII toxicity but have not
een associated with distal peripheral neuropathies. INH is one of
he medications most commonly associated with PN, and there are
stimates that as many as 10 % of patients receiving INH will develop
ome form of PN [26]. The drug’s mechanism of action against My-
obacterium tuberculosis (MTB) leads to depletion of pyridoxine (vita-
in B6), and it is the loss of pyridoxine that is toxic to the nerve [27].
eurotoxicity of INH can be ameliorated by giving pyridoxine supple-
entation, although high doses (>50 mg per day) of pyridoxine have
hemselves been shown to be toxic to the nerves [28]. Pyridoxine-
associated neuropathy tends to present with loss of vibration and
proprioception, and strict adherence to dosing recommendations of
pyridoxine should be followed to avoid this iatrogenic complication.
Of note, pyridoxine is only effective when given alone and not as part
of B complex vitamin therapy and should be discontinued after TB
therapy is complete.
The treatment of DR-TB is more complicated than that of pan-
susceptible disease and usually requires the use of multiple “second-
line” agents given for a period of 18–24 months [29]. Many of
these second-line agents have been associated with the develop-
ment of PN, including cycloserine (CS), ethionamide (Ethio), and the
ﬂuoroquinolones [30]. With highly-resistant forms of TB emerging,
new drugs-such as bedaquiline (BDQ) and delamanid (DEL)-and re-
purposed drugs-such as clofazimine (CFZ) and linezolid (LZD)-are be-
ing used with increasing frequency [31]. The impact of new chemical
entities on PNmay not yet be apparent, since the drugs are often eval-
uated in shorter trials (i.e. 8–24 weeks) prior to introduction into the
market, and such short administration and evaluation periods may
not be suﬃcient to document any true effects on PN.
In terms of re-purposed agents, several of the more commonly
used drugs have been associated with PN. One such agent is high-
dose INH, which may be associated with a higher rate of PN com-
pared with conventional doses [32]. CFZ has also be associated with
PN is some case series reports, largely due to accumulation of the
chemical substance in the peripheral nerves [33]. LZD is rapidly be-
coming a staple in the treatment of highly resistant forms of TB,
and one of the most common adverse events associated with this
drug is the development of PN [34]. In fact, the development of PN
s often the limiting factor in the dose and duration of LZD ther-
py. Multiple observational studies have shown high rates of PN in
ersons receiving LZD for DR-TB, with rates of 10–40% reported in
he literature [35,36]. Increasing rates of neuropathy are seen when
oses above 600 mg per day are given, and some alleviation of symp-
oms has been reported when the daily dose is lowered to 300 mg
aily [37,38]. The effect of pyridoxine supplementation on reduc-
ng LZD-associated PN has not been formally studied, but most pa-
ients being treatedwith LZD receive pyridoxine as part of standard of
are [39].
Because somany of themedications used for DR-TB treatment can
ause peripheral neuropathy, it is important that, whenever possible,
reatment for DR-TB be based on drug-susceptibility testing with a
oal of maximizing effectiveness while limiting toxicity. This may beneurological complications of HIV infection. Antiretroviral toxic neuropathy is also
ns it can affect all organs and systems.
workers
odes can cause isolated peripheral nerve injuries at speciﬁc locations via
m, and also degeneration of the myelin sheaths and axis cylinders
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Table 2
Medications associated with the development of PN in patients with TB.
Medication Class Medication Comment
DS-TB
INH The combination of INH and pyridoxine to form a hydrazone which is excreted in the urine, results in a relative deﬁciency
of biologically active pyridoxine.
EMB Optic nerve toxicity resulting from the administration of ETH is a well-recognized complication of therapy
DR-TB
CS A structural analogue of alanine, a central neurotransmitter. Interestingly d-cycloserine may help lessen pain and other
symptoms of PN caused by chemotherapy
Ethio A member of the thioamide family and structurally related to INH. Causes pyridoxine deﬁciency
High dose-INH
LZD May be a result of disrupted mitochondrial function in neurons.
ARVs
Stavudine (D4T) NRTI-associated mitochondrial dysfunction, inﬂammation and nutritional factors are implicated in the pathogenesis PN
among ART patients.
Didaonsine (ddI)
Zidovudine (AZT)
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cspecially important in patients on treatment for DR-TB, given that
heymay have also havemalnutrition both from their underlying dis-
ase as well as from anorexia, vomiting, and diarrhea associated with
he medications used in DR-TB treatment.
Finally, some of the medications used to treat co-morbid condi-
ions in persons with TB can also lead to the development of PN [40].
his is most commonly seen with certain antiretroviral (ARV) ther-
pies, especially the nucleoside reverse transcriptase inhibitors (NR-
Is) [41]. Another common co-morbid condition in HIV-infected pa-
ients is Kaposi’s Sarcoma which is treated with vinca alkaloids and
his treatment can also cause PN [42]. Table 2 lists the medications
sed for treating TB and its common co-morbid conditions that have
een associated with the development of PN
For most patients with TB, the cause of PN will be multifactorial
43], resulting from the disease itself, common co-morbid conditions,
nd the medications used to bring about cure.
In the case of RM, there are multiple potential factors that could be
ausing his signs and symptoms. These include his TB, his HIV, or his use
f alcohol. Several of his TB medications could be associated with PN,
ncluding his CS or his Ethio, and the patient is not receiving any pyri-
oxine. He has some exposure to alcohol and he may have exposure to
eavy metals or other chemicals through his job. His nutritional status
ould be contributing if he has a low body mass index, and he could have
ther undiagnosed pathology—including hypothyroidism given that he
s being treated with Ethio and PAS—that might be contributing to his
ymptoms.
resenting symptoms
Most TB patients who are experiencing nerve damage will show
o early signs or symptoms. Thus, routine evaluation and screening at
ll clinical encounters is crucial, as damage may be irreversible once
ymptoms begin. Routine screening questions should assess any neu-
ologic symptoms in the extremities (i.e. burning, tingling, etc.), any
roblems with walking or tripping, and the development of any sores
r injuries to the feet. Patients should be asked if the symptoms are
ilateral or unilateral.
When patients do present with symptoms, they are usually local-
zed to the feet and/or the hands in what is described as a classic
stocking and glove” distribution and they are often bilateral. Patients
ay note that the sensation is worse at night and may describe pain,
urning, numbing, cold, or restless sensations. Typically, the devel-
pment of these sensory symptoms precedes the development of any
uscular or proprioceptive symptoms, but not always, and patients
ay complain of tripping or losing their balance as well.In the case of RM, he is complaining of the most typical, early symp-
oms of PN, burning on the bottoms of his feet. The precise terms used
y patients to describe the sensation may vary depending on regional
ariation, but they generally involve an uncomfortable temperature or
ingling sensation on the bottoms of the feet and on the soles.
iagnosis and evaluation
All patients with TB should undergo routine evaluation for PN
t each clinical encounter. This includes the symptom screening de-
cribed above but also a formal assessment of strength and reﬂexes
n the extremities as well as an inspection of the hands and feet to as-
ess for any signs of injury, sores, or ulceration. Formal testing of the
eripheral nervous system is likely beyond the standard practice for
ost busy TB clinics. However, a targeted exam of the ankle reﬂexes
nd visual inspection of the feet and soles can be done quickly for all
atients being treated for TB, with more in-depth testing being done
n patients who report symptoms or having physical ﬁndings upon
creening [44].
A formal diagnosis on PN is usually made using neurophysio-
ogic tests such as electromyography (EMG), nerve conduction studies
NCS), and quantitative sensory tests (QST).In most TB endemic set-
ings, however, such objective quantitative assessments of the func-
ion of the peripheral nervous system may not be readily accessible
r may only be available at high cost in specialized centers [45]. For
his reason, it is recommended that a clinical diagnosis of PN be used
o guide management. While such a diagnosis may seem somewhat
ubjective, there are emerging scales that can be used to make the
iagnosis of PN in persons with TB [46]. One of these is known as
he Subjective Peripheral Neuropathy Score, where patients are asked
bout a set of symptoms, and, if present, asked to rate them on a scale
f 1-10 [47]. The numbers are then used to given and overall score to
etermine the severity of the PN. A version of the subjective portion
f the scale is included in Fig. 1 below, although this scale has not
een validated for use in persons with TB.
An algorithmic approach to diagnosing PN in persons with TB is
resented in Fig. 2.
Persons presenting with signs and symptoms of neuropathy who
lso have TB should be assessed for other co-morbid conditions that
ould impact the development of neuropathy. Thus all patients with
N should also undergo assessment for HIV, DM, hypothyroidism,
alnutrition, and alcohol use [48].
In the case of RM, he should have his history carefully reviewed
or any additional signs or symptoms of neuropathy and to determine
f he has any other exposures to alcohol, additional medications (in-
luding herbal supplements), and to see if he has any signs of DM or
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ALWAYS BEEN 
NORMAL
CURRENTLY 
ABSENT
MILD ←→ SEVERE
11 00 01-10
Symptoms R L
a. Pain, aching, or burning in feet, legs
b. "Pins and needles" in feet, legs
c. Numbness (lack of feeling) in feet, legs
Use the single highest severity score from Queson 1 above to obtain a subjecve sensory neuropathy score. If all 
severity scores are "00" or "11," the subjecve sensory neuropathy score will equal "0."
Subjecve Sensory Neuropathy Score (based on highest severity rang)
01 - 03 = grade of 1
04 - 06 = grade of 2
07 - 10 = grade of 3
11 or 00 = grade of 4
R L
Fig. 1. Subjective Peripheral Neuropathy Scale [63]
Instructions: Ask the subject to rate the severity of each symptom listed in Question 1 on a scale of 01 (mild) to 10 (most severe) for right and left feet and legs. Enter the score
for each symptom in the columns marked R (right lower limb) and L (left lower limb). If a symptom has been present in the past, but not since the last visit, enter “00 – Currently
Absent”. If the symptom has never been present, enter “11 – Always Been Normal”.
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chypothyroidism. He should undergo an assessment for neuropathy us-
ing the subjective neuropathy scale and should also have documenta-
tion of his strength and reﬂexes in the lower extremities bilaterally. His
feet should be carefully examined for any lesions or sores. He should
have a serum glucose, thyroid stimulating hormone and hemoglobin
tested.
Management
A two-phased approach to the management of PN is recom-
mended for all patients with TB [49]. The ﬁrst phase focuses on pre-
vention of the development or worsening of PN in all patients di-
agnosed with TB. The second focuses on treating the symptoms and
consequences of PN
Prevention
In terms of prevention, all patients with TB should be started
on pyridoxine supplementation at a dose of 50 mg daily. This drug
should be provided free of charge as part of routine management
for all persons with TB throughout the course of treatment. In ad-
dition, other nutritional deﬁciencies should be corrected as part of
optimal TB management. Patients who are using alcohol or other
drugs should be offered treatment or counseled in harm reduction
to minimize their use of substances that could contribute to PN.
All comorbid conditions should be optimally managed, and, when
possible, use of other medications that can cause PN should be
avoided.reatment
Once symptoms have developed, the management of PN can be
omplicated and depend on the type of problems the patient is hav-
ng as well as the severity of the symptoms [50]. Often PN is irre-
ersible, and can lead to signiﬁcant morbidity and lifelong disability,
nd cessation of ongoing nerve damage is a priority.
All medication doses and durations should be assessed, and, if
ossible without compromising the integrity of the TB treatment reg-
men, adjustments should be made. In many cases, however, espe-
ially among patientswith DR-TB, drug dose reduction or substitution
ay not be possible and management must then focus on preserving
unction and minimizing symptoms [51].
In terms of functional preservation, physical therapy with simple,
ome-based exercises can be successful in many ways [52]. Such ex-
rcises can focus on building compensatory muscle strength, preser-
ation of range of motion and prevention of the development of con-
ractures at joints, and adaptive motions to carry out daily activities
53]. Patients with PN should be provided with shoes that have thick
oles and are able to protect their extremities from injury or ulcera-
ion. Massage and acupuncture may also help preserve function [54].
alking aids—including crutches or canes—may be necessary in se-
ere cases. Patients with severe neuropathymay need counseling and
motional support [55].
In terms of medical management of PN symptoms, a number of
gents have been assessed with varying outcomes, although data
rom clinical trials in managing PN in persons with other medical is-
ues (i.e. cancer, DM) do not support the use of any of these agents
ith the exception of the selective serotonin reuptake inhibitors [56]
nd the gaba-eric agents [57]. These include topical agents such as
apsacin creams and lidocaine/lignocaine, but the effectiveness of
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At time of TB Diagnosis
•Baseline assessment and documentation of any symptoms of PN
•Baseline assessment and documentation of deep tendon reflexes
•Baseline assessment and documentation of appearance of feet
•Baseline testing for HIV, DM, alcohol use
•Nutritional screening and supplementation as needed
• Initiation of vitamin B6 
•Baseline review of concomitant therapy
No signs or symptoms 
suggestive of PN
Yes, has signs or 
symptoms 
suggestive of PN
Continue routine monitoring for PN
Assessment of signs or symptoms 
of PN, including sensory 
complaints, tripping, etc.
Assessment and documentation of 
DTRs
Assessment and documentation of 
appearance of feet Implement management plan for PN 
Halt offending agent
Preserve function
Minimize symptoms
Provide counseling and emotional support
In-depth assessment of PN
Administer subjective peripheral neuropathy scale
Formal neurologic assessment and documentation of 
findings
Review of medications and doses
Assess for other underlying causes (i.e. 
hypothyroidism, alcohol use, etc.)•
•
•
•
•
•
•
•
•
•
•
Fig. 2. Algorithmic Approach to Peripheral Neuropathy (PN) in Patients with TB
All patients with TB should have the following assessments and interventions done to minimize the impact of PN on their health.
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phese agents is questionable, and the cost and availability can be lim-
ting in many TB endemic settings. The goal of systemic therapy is
o target symptoms, as, to date, there have been no systemic ther-
pies that have been shown to reverse nerve damage or symptoms
58]. Systemic therapies tend to fall into four classes: 1) tricyclic an-
idepressants; 2) anticonvulsants; 3) selective serotonin reuptake in-
ibitors (SSRIs) and 4) GABA-ergic compounds [59] and are reviewed
n Table 3.
Table 4 provides a summary of the recommendations reviewed
n this section, with management strategies based on the severity of
ymptoms and physical ﬁndings.
In the case of RM, his PN is mild but he has multiple risk factors for
N that should be addressed in order to ensure his symptoms do not
rogress. He is started on pyridoxine and he is counseled to stop con-
uming alcohol. His body mass index is normal and he does not have any
igns or symptoms of nutritional deﬁciencies. His lab tests are within
ormal limits. The suspected cause is his TB regimen but his clinicians
etermine that starting pyridoxine at a dose of 50 mg by mouth daily is
he best initial management step. He is also counseled on further signs
nd symptoms that could indicate a worsening of neuropathy and told
o report to clinic should he note any of these problems.rognosis and impact
Although PN is a common problem seen in persons with TB, there
s little known about the impact of this problem on the long-term
ealth and functionality of persons who develop the condition [60].
lthough early recognition of signs or symptoms may allow for pro-
ression of PN to be halted, most PN is permanent and irreversible
61]. Thus, its ability to have long-term consequences for TB patients
s high. In addition to these long-term functional consequences, the
evelopment of PN can be distressing for patients and may risk ad-
erence to long-term TB treatment [62].
uture research
In spite of the fact that PN is one of the most common neurologic
equelae seen in persons with TB, there is little know about its preva-
ence, its optimal management, and the overall health and quality of
ife impact it has, even on those patients who are ultimately cured
f their TB disease. There is a need for targeted research on PN in TB
atients, with a focus on effective prevention, early and systematic
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Table 3
Commonly used agents and mechanisms of action for the treatment of PN [64-67].
Drug class Agents Dosing Adverse events Comments
Topical
Capsacin No clinical trials evidence to support its
use
Lidocaine (5% patch) 3 patches per day Rash or erythema No clinical trials evidence to support its
use
Tricyclics
Amytriptyline 10–25 mg every night Cardiovascular disease (needs screening
for QTc prolongation), anticholinergic
effects, interact with drugs
metabolized by cytochrome P450 2D6
(e.g., cimetidine, phenothiazine)
Avoid with LZD given possible serotonin
syndrome; No clinical trials evidence
to support its use
Anticonvulsants
Carbamazepine 100–200 mg twice per day Skin rashes No clinical trials evidence to support its
use
SSRIs
Duloxetine 60–120 mg per day Serotonin syndrome, weight gain Clinical trials from oncology support its
use; Avoid with LZD given possible
serotonin syndrome
GABA-eric
Gabapentin 100–300 mg every night or 100–300 mg
three times daily
Somnolence, dizziness, GI symptoms,
mild edema, cognitive impairment
(elderly), exacerbation of gait
problems
Clinical trials support its use at doses of
1800–3600 mg per day.
Pregabalin 25–50 mg 3 times per day Dizziness, somnolence, xerostomia,
edema, blurred vision, decreased
concentration
Limited clinical trials evidence to
support its use
Table 4
Recommended management of peripheral neuropathy.
Grade of disease Interventions Comments
Not yet present Assessment at every visit Preventive measures
Prevention with pyridoxine
Treatment of co-morbidities
alcohol and smoking cessation counseling
Mild Treatment of co-morbidities alcohol and smoking cessation counseling
increase dose of pyridoxine assessment of function at every visit
Moderate Treatment of co-morbidities
alcohol and smoking cessation counseling
increase dose of pyridoxine
assessment of function at every visit
reduce or alter dosage of neurotoxic drugs
symptomatic treatment
Severe Treatment of co-morbidities alcohol and smoking cessation counseling
Maximum dose of pyridoxine
Assessment of function at every visit
reduce or alter dosage of neurotoxic drugs – consider stopping drug if there is alternative
Symptomatic treatment with amitriptyline, duloxetine, gabapentin etc.
i
o
s
p
Rdiagnosis at the primary level, and effective treatment and mitiga-
tion strategies.
Conclusion
PN is a common condition, affecting many people with TB dis-
ease. The cause is likely multifactorial, presenting a complex clinical
scenario, but the consequences can be severe and permanent hence
a need for vigilance in management. Prevention strategies are key,
and all persons being treated for TB should receive concomitant pyri-
doxine supplementation, and correction of any modiﬁable risk fac-
tors. All TB patients should be routinely screened for PN and have
reﬂexes tested as well as a visual inspection of the feet at each exam.
The presence of neuropathic symptoms, decreased ankle reﬂexes, and
decreased distal sensations, regardless of distal muscle weakness and
atrophy, makes the diagnosis of PN likely. Management should focus
on halting damage to the nerve—although care should be taken not
to compromise the TB regimen—and alleviating symptoms. Counsel-ng and emotional support may be needed in those with severe forms
f disease. Better research is needed to determine ideal management
trategies and to contribute to better health and quality of life for all
ersons who are survivors of TB.
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